logo-loader

ReNeuron Group puts the focus on exosome technology

Last updated: 08:40 08 Nov 2023 GMT, First published: 06:54 15 Mar 2021 GMT

Snapshot

  • ReNeuron shares suspended as urgent cash injection needed
  • ReNeuron Group PLC shares soar on impressive data from latest breakthrough
  • ReNeuron Group’s investment potential ‘remains intact’, 2024 cash runway secured, says Liberum
  • ReNeuron has extended cash runway as it focuses on validating its exosome platform
dna strand

About the company

ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, its CustomEX platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.

ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.

How it is doing

05 Feb 2024

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it has requested its shares be suspended pending clarification of its financial position. 

The company said in a statement that despite efforts to manage working capital, it is in a "highly constrained financial position" and needs additional financing urgently to continue as a going concern.

Although directors continue to explore options, including potential sales of physical and intellectual assets, the lack of new funding means discussions are being initiated with creditors and staff are being put at risk of redundancy.

If a solution is not found in the short term, the company will be put into administration and any value returned to shareholders not yet known.

08 Nov 2023

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) is to present in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of its CustomEX drug delivery platform at Cell 2023 in London.

Data to be presented shows the significant improvement in targeting and delivery of payloads that can be achieved through the careful selection of specific exosomes from different cell sources, said the company.

04 Sep 2023

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it has taken an important step forward with plans to differentiate its exosome platform by generating in vivo (living tissue) data highlighting its distinct organ and cellular targeting capabilities.

Iain Ross, executive chairman, said: "On the basis of this data the company will now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads."

Insight: ReNeuron Group PLC shares soar on impressive data from latest breakthrough

11 Oct 2021

The 38% rise in the share price of ReNeuron Group PLC (AIM:RENE) probably hasn’t come as a huge surprise to those that follow the stem cell specialist.

There was quite a lot to unpack from Monday’s announcement – one in which it said its exosome technology had delivered therapeutic proteins to a hard to access region of the human brain.

What the brokers say

13 Feb 2023

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF)’s house broker Liberum has restated a buy rating with a cash runway stretched out to 2024 following the AIM-listed biotechnology company’s recent restructuring.

In Liberum’s view: “The core investment hypothesis remains intact, and we believe that the selective delivery of complex drug modalities could be highly attractive to partners.”

Plotting a path beyond ReNeuron’s 2024 cash runway hinges on the successful monetisation of its exosome drug delivery system CustomEx, which uses proprietary stem cells to create highly customisable exosomes that be used to deliver next-generation target therapies for patients.

What management says

17 Feb 2023

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway.

ReNeuron will conduct head-to-head studies with its competitors to produce the data needed to achieve the commercial validation of the platform, Ross said. The company's cash runway has also been extended into 2024 following a restructuring undertaken in 2022, he added. 

ReNeuron has extended cash runway as it focuses on validating its exosome...

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors...

on 17/2/23